Skip to content
buyWeak

Jay S. Duker bought $20k of EYPT

President and CEO at EyePoint Pharmaceuticals, Inc.. 1,500 shares at an average of $13.15, traded Mar 16, 2026, filed Mar 16, 2026.

Conviction score
29
Value
$20k
1,500 shares
Holdings after
100,665
+2% from before
From 52-week low
+226%
low $4.13, close $13.45
From 52-week high
-29%
high $18.85, as of Mar 16, 2026

Score components

  • Role
    CEO
    +25
  • Trade size
    $20k at market
    0
  • Relative to holdings
    Holdings up 1.5%
    0
  • Price context
    29% below the 52-week high
    +4
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +8.8%, 3m -10.2%, 6m -68.4%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

EYPTOct 12, 2026 · close 3.32
Since filing Mar 16, 2026: -75.3%SPY +17.2% · excess -92.5%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001630864-26-000006, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 16, 2026POpen-market purchase
Common Stockindirect: By Family Trust
+1,500$13.15$20k100,665Mar 16, 2026

Related signals

Other insiders at EyePoint Pharmaceuticals, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
36Weak
EYPTbuy
EyePoint Pharmaceuticals, Inc.
Karen L. Zaderej
director
$52k
10,600 shares
+28%
8Weak
EYPTsell10b5-1
EyePoint Pharmaceuticals, Inc.
Ramiro Ribeiro
Chief Medical Officer
$73k
4,875 shares
-100%
6Weak
EYPTsell10b5-1
EyePoint Pharmaceuticals, Inc.
Ramiro Ribeiro
Chief Medical Officer
$37k
2,437 shares
-100%
6Weak
EYPTsell10b5-1
EyePoint Pharmaceuticals, Inc.
Ramiro Ribeiro
Chief Medical Officer
$44k
2,438 shares
-100%
6Weak
EYPTsell10b5-1
EyePoint Pharmaceuticals, Inc.
Ramiro Ribeiro
Chief Medical Officer
$37k
2,437 shares
-100%
21Weak
EYPTsell10b5-1
EyePoint Pharmaceuticals, Inc.
Ramiro Ribeiro
Chief Medical Officer
$727k
42,544 shares
-100%
40Moderate
EYPTsell 2
EyePoint Pharmaceuticals, Inc.
Cormorant Asset Management, LP
other
$942k
60,000 shares
-1%
14Weak
EYPTsell 210b5-1
EyePoint Pharmaceuticals, Inc.
Nancy Lurker
Executive Vice Chair
$140k
9,300 shares
-4%
3Weak
EYPTsell 210b5-1
EyePoint Pharmaceuticals, Inc.
Nancy Lurker
Executive Vice Chair
$10k
700 shares
-0%
20Weak
EYPTsell10b5-1
EyePoint Pharmaceuticals, Inc.
Ramiro Ribeiro
Chief Medical Officer
$32k
2,722 shares
-100%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Jay S. Duker bought $20k of EYPT | InsiderTell